01 December 2011
Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirinTatsuya FujinoABCDE, Makoto NakamutaABDG, Yoko AoyagiB, Motoyuki KohjimaB, Takeaki SatohB, Mika FukudaB, Hiromi IshibashiB, Hiroshi YatsuhashiABD, Munechika EnjojiDEFG
Med Sci Monit 2011; 17(12): CR687-691
Background: We aimed to assess differences in early viral dynamics following treatment with either peg-IFNalpha2a or peg-IFNalpha2b in combination with ribavirin in patients with chronic genotype 1b HCV infection.
Material/Methods: Sixty-one patients in the peg-IFNalpha2a + ribavirin treatment (group alpha2a) and 88 patients in the peg-IFNalpha2b + ribavirin treatment (group alpha2b) were retrospectively analyzed. The early dynamics of HCV RNA over 12 weeks were evaluated. Sustained virological response (SVR) was defined as undetectable HCV RNA at week 24 after end of therapy. First- (day 0–1) and second-phase (day 1–28) viral decline rates were calculated in accordance with theoretical formulae.
Results: Baseline HCV RNA concentrations were almost similar between the 2 groups. In group alpha2a, viral decline was significantly greater than in group alpha2b at weeks 4, 8, and 12. In group alpha2a, viral decline was significantly greater in SVR patients than in non-SVR patients at week 2, whereas significantly greater viral decline in SVR patients was found during weeks 1–12 in group alpha2b. The first-phase viral decline rate was significantly larger in group alpha2a than in group alpha2b (1.31±0.84 vs. 0.70±0.97 log IU/mL/day; p<0.0001). Within SVR patients, first-phase viral decline rate was significantly larger in group α2a compared with group alpha2b (1.45±0.85 vs. 0.78±1.0 log IU/mL/day; p<0.0001). Second-phase viral decline rate was comparable between the groups.
Conclusions: Peg-IFNalpha2a showed earlier viral decline than peg-IFNalpha2b and the difference was obvious, especially in the first-phase viral decline.
Keywords: Models, Biological, Polyethylene Glycols - therapeutic use, Kinetics, Interferon-alpha - therapeutic use, Hepatitis C, Chronic - virology, Hepacivirus - physiology, Genotype, Drug Therapy, Combination, Antiviral Agents - therapeutic use, RNA, Viral - blood, Recombinant Proteins - therapeutic use, ribavirin, Viremia - virology
01 November 2021 : EditorialEditorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems During the COVID-19 Pandemic?
Med Sci Monit 2022; 28:e935299
26 November 2021 : EditorialEditorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
Med Sci Monit In Press; DOI: 10.12659/MSM.935624
08 November 2021 : Database AnalysisVirtual Screening and Molecular Docking to Study the Mechanism of Chinese Medicines in the Treatment of Cor...
Med Sci Monit In Press; DOI: 10.12659/MSM.934102
01 November 2021 : EditorialEditorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems Duri...
Med Sci Monit 2022; 28:e935299
29 Nov 2021 : Database AnalysisIntegrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcin...
Med Sci Monit In Press; DOI: 10.12659/MSM.934937
26 Nov 2021 : Clinical ResearchSerum Uric Acid Levels in Relation to Atrial Fibrillation: A Case-Control Study
Med Sci Monit In Press; DOI: 10.12659/MSM.934007
26 Nov 2021 : Database AnalysisNetwork Pharmacology Integrated Molecular Docking Revealed the Mechanism of Jianpi Yiqi Taohua Decoction Ag...
Med Sci Monit In Press; DOI: 10.12659/MSM.933537
Most Viewed Current Articles
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700